This topic contains a solution. Click here to go to the answer

Author Question: Who mostly benefits from crowdfunding? a) Entrepreneurs only b) Fund-collecting sites c) ... (Read 70 times)

Shelles

  • Hero Member
  • *****
  • Posts: 582
Who mostly benefits from crowdfunding?
 
  a) Entrepreneurs only
  b) Fund-collecting sites
  c) Consumers and donors
  d) Entrepreneurs and communities

Question 2

Erin works at a think tank in Washington, DC. She is a progressive liberal and, as most of her colleagues are around her age and come from similar backgrounds, she makes the assumption that her colleagues are too, even though a large percentage of
 
  them do not identify as such. Erin has fallen susceptible to ________. a) social network conditioning
  b) social comparison
  c) implicit attitudes
  d) pluralistic ignorance



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

kardosa007

  • Sr. Member
  • ****
  • Posts: 300
Answer to Question 1

d

Answer to Question 2

d




Shelles

  • Member
  • Posts: 582
Reply 2 on: Jun 22, 2018
Wow, this really help


steff9894

  • Member
  • Posts: 337
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

The U.S. Pharmacopeia Medication Errors Reporting Program states that approximately 50% of all medication errors involve insulin.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

Approximately one in four people diagnosed with diabetes will develop foot problems. Of these, about one-third will require lower extremity amputation.

Did you know?

Barbituric acid, the base material of barbiturates, was first synthesized in 1863 by Adolph von Bayer. His company later went on to synthesize aspirin for the first time, and Bayer aspirin is still a popular brand today.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library